Paper Details
BPB Reports
Vol. 6
No. 4
p.141-143
2023
Report
Overcoming Native Macrolide and Acquired Multidrug-Resistant Pseudomonas aeruginosa with Azithromycin and Polymyxin B Nonapeptide
- Yukihiro Asami (Graduate School of Infection Control Sciences, Kitasato University / Ōmura Satoshi Memorial Institute, Kitasato University / yasami@lisci.kitasato-u.ac.jp)
Aoi Kimishima
1)
2)
,
Hidehito Matsui
1)
2)
,
Kazunari Sakai
3)
,
Masako Honsho
1)
2)
,
Sota Honma
1)
2)
,
Miho Sugamata
1)
2)
,
Naozumi Kondo
1)
,
Serino Maruyama
1)
,
Paul Wasuwanich
4)
,
Kamrun Naher
2)
,
Naoaki Arima
3)
,
Kazutoyo Abe
3)
,
Hideaki Hanaki
1)
2)
3)
,
Yukihiro Asami
1)
2)
1) Graduate School of Infection Control Sciences, Kitasato University , 2) Ōmura Satoshi Memorial Institute, Kitasato University , 3) Research Management Department, Kowa Company Ltd. , 4) University of Florida College of Medicine
1) Graduate School of Infection Control Sciences, Kitasato University , 2) Ōmura Satoshi Memorial Institute, Kitasato University , 3) Research Management Department, Kowa Company Ltd. , 4) University of Florida College of Medicine
Received: June 21, 2023;
Accepted: July 23, 2023;
Released: August 04, 2023
Keywords: azithromycin (AZM), polymyxin B nonapeptide (PMBN), Pseudomonas aeruginosa (P. aeruginosa), multidrug-resistant clinical isolates
Abstracts
Semi-synthetic antibiotic, azithromycin (AZM) does not show significant bactericidal activity against Pseudomonas aeruginosa (P. aeruginosa). We focused on potential for AZM as a multi targeting drug against P. aeruginosa and found combination of AZM and Polymyxin B nonapeptide (PMBN) to increase the permeability of the outer membrane. This combination is effective for P. aeruginosa including multidrug-resistance clinical isolates and shows 32-512-fold potentiation of the anti-P. aeruginosa activity of AZM. We found a great opportunity to create new anti-P. aeruginosa drug candidates based on AZM and PMBN.
